2024-02-052024-02-052022-01-02Zorlu, Ö. vd. (2020). "Predictors of drug survival of biologic therapies in psoriasis patients". Journal of Dermatological Treatment, 33(1), 437-442.0954-66341471-1753https://www.tandfonline.com/doi/full/10.1080/09546634.2020.1763240https://hdl.handle.net/11452/39514Introduction: We aimed to investigate the clinical, immunological, and genetic factors affecting the response to anti-TNF alpha (tumor necrosis factor-alpha) and interleukin-12/23 therapies and drug survivals. Methods: A total of 180 patients were divided into two groups: 89 patients who used at least two biologic agents, with the initial biologic agent used less than 12 months (group A), and 91 biologic-naive patients who have been receiving a single biologic agent for more than 12 months (group B). ELISA (enzyme-linked immunosorbent assay) was used to analyze anti-drug antibodies (ADAs) in blood samples. Clinical data of the patients were retrospectively analyzed. HLA-SSO (sequence-specific oligonucleotide) Typing Kits were used for HLA-C typing. IBM SPSS v.21 was used for statistical analysis. Results: Infliximab had the longest drug survival as the first biologic agent in group A (p = .015). Etanercept had the lowest ADA count compared to the other anti-TNF agents (p = .001). HLA-Cw6 negativity, late-onset psoriasis, smoking and alcohol use were determined to be risk factors for treatment failure in group A. HLA-Cw6 was found to be associated with type I psoriasis (p = .000). Conclusions: Although our study is retrospective of a relatively low number of patients, this is a preliminary study focusing on two different patient populations based on therapy response.eninfo:eu-repo/semantics/closedAccessDermatologyAnti-TNFBiologicsHLA-Cw6PsoriasisClinical-responseObservational cohortBritish associationUstekinumabPolymorphismsEtanerceptAdalimumabHLA-C-asterisk-06AntibodiesAlleleAdalimumabBiological therapyEtanerceptHumansInfliximabPharmaceutical preparationsPsoriasisRetrospective studiesTumor necrosis factor inhibitorsArticle0005342854000012-s2.0-8508481589043744233132351141https://doi.org/10.1080/09546634.2020.1763240DermatologyPustulosis Palmoplantaris; Secukinumab; Nail DiseasesAdalimumabBiological productDrug antibodyEtanerceptHLA C antigenInfliximabInterleukin 12Interleukin 23UstekinumabAdalimumabDrugEtanerceptInfliximabTumor necrosis factor inhibitorAdultAlcohol consumptionArticleBiological therapyBlood samplingData analysis softwareDisease severityEnzyme linked immunosorbent assayFamily historyFemaleGene frequencyHeredityHLA systemHLA typingHumanLate onset disorderMajor clinical studyMaleMiddle agedMail psoriasisPsoriasisPsoriasis vulgarisPsoriatic arthritisRetrospective studyRetrospective studyRisk factorSmokingSurvival predictionTreatment failureTreatment responseBiological therapy